Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma, Follicular 1Arthritis, Rheumatoid 1

Interventions

Methotrexate 3olokizumab 2veltuzumab 1upadacitinib 1tocilizumab 1mavrilimumab 1golimumab 1andecaliximab 1Vaccines 1Tumor Necrosis Factor Inhibitors 1TACI receptor-IgG Fc fragment fusion protein 1Saline Solution 1RC-18 1Interleukin 1 Receptor Antagonist Protein 1ISIS104838 1Herpes Zoster Vaccine 1Bortezomib 1Adalimumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Arthritis, Rheumatoid × RC-18 × Clear all
NCT02882087 2019-04-03

A Study of the Efficacy and Safety of TACI-antibody Fusion Protein Injection (RC18) in Subjects With Inadequate Response to TNF-α Antagonists Due to Treat Moderate and Severe Rheumatoid Arthritis

RemeGen Co., Ltd.

Phase 2 Terminated
60 enrolled
Lymphoid

Arthritis, Rheumatoid, Lymphoma, Follicular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡